Lenalidomide provide better progression free survival than thalidomide and bortezomib in the first relapse of multiple myeloma patients after autologous transplantation | AVESİS

Hacettepe University Research Information System

Lenalidomide provide better progression free survival than thalidomide and bortezomib in the first relapse of multiple myeloma patients after autologous transplantation

Copy For Citation

Malkan Ü. Y., Buyukasik Y., Demiroglu H., Ciftciler R., Gunes G., Okay M., ...More

9th International Eurasian Hematology Oncology Congress (EHOC), İstanbul, Turkey, 17 - 20 October 2018, vol.73, (Summary Text)

Publication Type: Conference Paper / Summary Text
Volume: 73
City: İstanbul
Country: Turkey
Hacettepe University Affiliated: Yes